ALS Centre Netherlands
Foundation year1998
DirectorProf. dr. Leonard van den Berg
Principal investigatorProf. dr. Leonard H. van den Berg, Prof. dr. Jan Veldink, Prof. dr. Jeroen Pasterkamp
The ALS Centre Netherlands is the centre of expertise on ALS, PLS and PMA in the Netherlands. The centre is a cooperation of the University Medical Centre Utrecht and the Amsterdam Medical Centre. The centre schedules all diagnostic research and consultations for each patient on one day. More than 500 patients are diagnosed with ALS, PLS, PMA or one of its mimics each year. The ALS Centre Netherlands initiated Project Mine (www.projectmine.com), the largest research of the genetic basis of ALS worldwide. Additionally, research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.
Contact Information
Restricted information
Serving population
100.000 to 1.000.000
Population based register
Clinic based register
Geographically matched controls
Number of muscle samples
0
Number of skin samples
57
Number of spinal cord samples
25
Number of brain samples
25
Number of IPS cell samples
In development
Banks
TypeALS PatientsControlsOther
Dna Bank
2650
3200
0
Serum Bank
2160
3080
0
RNA Bank
500
2380
0
MRI
443
409
105 PSMA, 81 PLS, 83 mimics
Clinical management research
Neuro epidemiology
Neuro physiology
Neuro imaging
Neuro psychology
Neuro pathology
Genomics
Transcriptomics
Metabolomics
Publication
- Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; for the EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology 2013 Nov;12(11):1059-67
- Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, van den Berg LH, Veldink JH, Vucic S, Kiernan MC. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12(3):310-22.
- Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE, Zhernakova A, Zhernakova DV, Veldink JH, Van den Berg LH, Karjalainen J, Withoff S, Uitterlinden AG, Hofman A, Rivadeneira F, \’t Hoen PA, Reinmaa E, Fischer K, Nelis M, Milani L, Melzer D, Ferrucci L, Singleton AB, Hernandez DG, Nalls MA, Homuth G, Nauck M, Radke D, Völker U, Perola M, Salomaa V, Brody J, Suchy-Dicey A, Gharib SA, Enquobahrie DA, Lumley T, Montgomery GW, Makino S, Prokisch H, Herder C, Roden M, Grallert H, Meitinger T, Strauch K, Li Y, Jansen RC, Visscher PM, Knight JC, Psaty BM, Ripatti S, Teumer A, Frayling TM, Metspalu A, van Meurs JB, Franke L. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature Genet 2013;45(10):1238-43.
- Van Blitterswijk M, Wang ET, Friedman BA, Keagle PJ, Lowe P, Leclerc AL, van den Berg LH, Housman DE, Veldink JH, Landers JE. Characterization of FUS Mutations in Amyotrophic Lateral Sclerosis Using RNA-Seq. PLoS One 2013;8(4):e60788.
- Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E, Veldink JH, van den Berg LH. SMN1 gene duplications are associated with sporadic ALS. Neurology. 2012 Mar 13;78(11):776-80. Epub 2012 Feb 8. PubMed PMID: 22323753; PubMed Central PMCID: PMC3304946.
Have a look at the researchgate pages with full-text publications